At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
MMV688533drug
Likely dose
MMV688533 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study to Assess the Safety, Tolerability and Antimalarial Activity of MMV533 Against Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating MMV688533 for Malaria. Completed, enrolled 9 participants across 1 site.
Detailed Summary
A Phase 1b study to assess the safety, tolerability and antimalarial activity of MMV533 against Plasmodium falciparum 3D7 blood stage infection in healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesAustralia
CollaboratorsNucleus Network Ltd, Southern Star Research
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartMar 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedJan 25, 2022
Enrollment StartMar 30, 2022
Primary CompletionSep 2, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.4 years ago
Interventions
MMV688533drug
Not exceeding 200mg